Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Operating expense | 5M | 32.1% |
| Net Income | -4M | 37.2% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 111M | 4.3% |
| Total Liabilities | 1.6M | 14.4% |
| Total Equity | 109M | 4.1% |
| Shares Outstanding | 44M | 0.1% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -4.2M | 38.7% |
EPS
Financial Highlights for ESSA Pharma in Q2 '25
Operating Expenses for this period were 5M, showing a -32.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -4M, showing a 37.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
